See more : Swiss Prime Site AG (SWPRF) Income Statement Analysis – Financial Results
Complete financial analysis of Soligenix, Inc. (SNGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Soligenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Maritime Resources Corp. (MRTMF) Income Statement Analysis – Financial Results
- Ynvisible Interactive Inc. (YNVYF) Income Statement Analysis – Financial Results
- Gérard Perrier Industrie S.A. (PERR.PA) Income Statement Analysis – Financial Results
- Seiko Electric Co., Ltd. (6653.T) Income Statement Analysis – Financial Results
- DFP Healthcare Acquisitions Corp. (DFPHW) Income Statement Analysis – Financial Results
Soligenix, Inc. (SNGX)
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 839.36K | 948.91K | 824.27K | 2.36M | 4.63M | 5.24M | 5.43M | 10.45M | 8.77M | 7.04M | 3.22M | 3.14M | 7.66M | 1.95M | 2.82M | 2.31M | 1.26M | 2.31M | 3.08M | 997.48K | 83.82K | 0.00 | 0.00 | 0.00 | 1.00 | 200.00K | 100.00K | 0.00 |
| Cost of Revenue | 742.05K | 550.82K | 728.64K | 1.82M | 3.57M | 4.60M | 4.31M | 8.43M | 6.88M | 5.31M | 2.54M | 2.59M | 2.11M | 1.64M | 1.48M | 1.89M | 943.39K | 1.97M | 2.07M | 936.64K | 76.20K | 0.00 | 0.00 | 0.00 | -1.41M | -1.70M | -500.00K | 0.00 |
| Gross Profit | 97.31K | 398.09K | 95.63K | 538.50K | 1.06M | 643.73K | 1.12M | 2.02M | 1.89M | 1.73M | 679.87K | 551.55K | 5.55M | 309.23K | 1.33M | 423.83K | 314.63K | 347.95K | 1.01M | 60.85K | 7.62K | 0.00 | 0.00 | 0.00 | 1.41M | 1.90M | 600.00K | 0.00 |
| Gross Profit Ratio | 11.59% | 41.95% | 11.60% | 22.82% | 22.95% | 12.28% | 20.66% | 19.29% | 21.51% | 24.55% | 21.09% | 17.54% | 72.49% | 15.88% | 47.31% | 18.35% | 25.01% | 15.04% | 32.80% | 6.10% | 9.09% | 0.00% | 0.00% | 0.00% | 140,775,100.00% | 950.00% | 600.00% | 0.00% |
| Research & Development | 3.31M | 7.94M | 8.39M | 15.15M | 8.12M | 6.75M | 5.51M | 4.30M | 5.40M | 5.09M | 5.07M | 2.61M | 6.27M | 5.68M | 4.52M | 1.73M | 3.10M | 4.62M | 3.68M | 3.66M | 2.73M | 2.94M | 2.47M | 956.74K | 2.03M | 3.10M | 1.80M | 906.46K |
| General & Administrative | 4.48M | 6.69M | 4.85M | 3.98M | 3.48M | 2.95M | 3.21M | 3.43M | 3.60M | 3.40M | 2.77M | 2.56M | 0.00 | 2.50M | 2.86M | 2.15M | 0.00 | 0.00 | 0.00 | 0.00 | 2.51M | 1.97M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 68.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.48M | 6.69M | 4.85M | 3.98M | 3.48M | 2.95M | 3.21M | 3.43M | 3.60M | 3.40M | 2.77M | 2.63M | 2.24M | 2.50M | 2.86M | 2.15M | 3.54M | 3.11M | 2.16M | 2.32M | 2.51M | 2.99M | 1.97M | 2.10M | 3.05M | 3.50M | 1.50M | 317.24K |
| Other Expenses | 0.00 | -132.87K | -174.77K | -95.36K | -433.59K | 0.00 | 0.00 | 3.43M | 3.60M | 3.40M | 2.77M | 2.63M | 2.24M | 0.00 | 0.00 | 0.00 | 3.54M | 3.93M | 2.16M | 2.32M | 2.51M | 2.99M | 12.15M | 2.10M | 4.45M | 5.20M | 2.00M | 0.00 |
| Operating Expenses | 7.80M | 14.50M | 13.06M | 19.03M | 11.17M | 9.70M | 8.72M | 7.72M | 9.00M | 8.49M | 7.84M | 5.24M | 8.51M | 8.19M | 7.38M | 3.88M | 6.64M | 8.55M | 5.84M | 5.98M | 5.23M | 5.93M | 14.63M | 3.06M | 6.48M | 8.30M | 3.80M | 1.26M |
| Cost & Expenses | 8.54M | 15.05M | 13.79M | 20.85M | 14.74M | 14.30M | 13.03M | 16.16M | 15.88M | 13.80M | 10.38M | 7.84M | 10.62M | 9.83M | 8.87M | 5.77M | 7.59M | 10.51M | 7.91M | 6.91M | 5.31M | 5.93M | 14.63M | 3.06M | 5.08M | 6.60M | 3.30M | 1.26M |
| Interest Income | 0.00 | 822.61K | 904.50K | 10.88K | 148.97K | 159.01K | 29.91K | 0.00 | 0.00 | 1.31K | 1.96K | 6.20K | 7.44K | 12.07K | 21.92K | 37.07K | 164.85K | 41.51K | 114.79K | 66.54K | 28.71K | 105.68K | 424.03K | 747.07K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 49.13K | 822.61K | 862.58K | 10.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 742.00 | 2.68K | 3.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -35.84K | -35.84K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.55K | 137.28K | 150.45K | 193.04K | 177.56K | 44.06K | 68.56K | 89.93K | 247.46K | 245.79K | 230.07K | 230.63K | 226.03K | 185.70K | 175.60K | 149.18K | 119.57K | 137.04K | 194.28K | 302.45K | 226.14K | 345.50K | 188.53K | 156.86K | 1.41M | 1.70M | 500.00K | 204.46K |
| EBITDA | -7.85M | -14.11M | -12.23M | -18.23M | -9.36M | -9.01M | -7.53M | -5.62M | -6.86M | -6.52M | -6.93M | -4.45M | -2.73M | -7.45M | -5.86M | -3.31M | -6.21M | -8.02M | -4.64M | -5.61M | -5.00M | -6.45M | -3.86M | -2.90M | -3.67M | -4.80M | -2.70M | -1.06M |
| EBITDA Ratio | -935.58% | -1,483.34% | -1,565.17% | -781.06% | -216.96% | -171.99% | -138.52% | -72.27% | -64.56% | -84.51% | -101.47% | -141.83% | -35.58% | -394.36% | -208.57% | -143.13% | -493.33% | -313.28% | -150.88% | -562.94% | -5,934.78% | 0.00% | 0.00% | 0.00% | -80,576,000.00% | 5,250.00% | -2,900.00% | 0.00% |
| Operating Income | -7.70M | -14.11M | -12.97M | -18.49M | -10.11M | -9.06M | -7.59M | -5.71M | -7.11M | -10.76M | -7.16M | -4.69M | -2.96M | -7.88M | -6.05M | -3.46M | -6.33M | -8.20M | -4.84M | -5.92M | -5.23M | -5.93M | -14.63M | -3.06M | -5.08M | -6.40M | -3.20M | -1.26M |
| Operating Income Ratio | -917.12% | -1,486.55% | -1,573.05% | -783.71% | -218.31% | -172.83% | -139.79% | -54.64% | -81.09% | -152.79% | -221.97% | -149.16% | -38.63% | -404.51% | -214.89% | -149.59% | -502.94% | -354.50% | -157.20% | -593.21% | -6,236.06% | 0.00% | 0.00% | 0.00% | -507,562,800.00% | -3,200.00% | -3,200.00% | 0.00% |
| Total Other Income/Expenses | -210.59K | -714.37K | -449.60K | 61.09K | 574.75K | 159.01K | 29.91K | 1.93M | -1.21M | 3.44M | -3.65M | 6.20K | 7.44K | 246.03K | 16.84K | 33.80K | 162.44K | 36.20K | 114.79K | 45.54K | -61.65K | -5.92K | -5.92K | -2.43M | -2.86M | -15.20M | 200.00K | 74.85K |
| Income Before Tax | -7.91M | -14.95M | -13.42M | -18.53M | -9.97M | -8.90M | -7.56M | -3.78M | -8.32M | -7.32M | -10.81M | -4.68M | -2.95M | -7.63M | -6.05M | 0.00 | -6.33M | -9.02M | 0.00 | -5.92M | -5.29M | -14.63M | -14.63M | -5.49M | -7.94M | -21.60M | -3.00M | -1.19M |
| Income Before Tax Ratio | -942.21% | -1,575.84% | -1,627.59% | -785.16% | -215.26% | -169.80% | -139.23% | -36.13% | -94.89% | -103.99% | -335.26% | -148.97% | -38.53% | -391.88% | -214.97% | 0.00% | -503.05% | -389.79% | 0.00% | -593.15% | -6,309.62% | 0.00% | 0.00% | 0.00% | -793,774,600.00% | -10,800.00% | -3,000.00% | 0.00% |
| Income Tax Expense | -1.77M | -1.15M | -864.74K | -836.89K | -610.68K | 159.01K | -416.81K | -530.14K | -488.93K | -616.87K | -750.36K | -521.46K | -574.16K | -245.81K | -16.84K | -33.80K | -162.44K | -36.20K | -114.79K | -45.54K | 61.65K | -965.43K | 5.92K | 1.74M | 2.43M | 15.40M | 0.00 | 0.00 |
| Net Income | -6.14M | -13.80M | -12.55M | -17.69M | -9.36M | -8.90M | -7.15M | -3.25M | -7.83M | -6.71M | -10.06M | -4.16M | -2.38M | -7.39M | -6.03M | -3.42M | -6.16M | -8.16M | -4.72M | -5.87M | -5.29M | -4.97M | -14.63M | -4.80M | -7.50M | -21.80M | -3.20M | -1.19M |
| Net Income Ratio | -731.60% | -1,454.12% | -1,522.68% | -749.69% | -202.07% | -169.80% | -131.56% | -31.06% | -89.31% | -95.23% | -311.99% | -132.39% | -31.04% | -379.26% | -214.29% | -148.12% | -490.03% | -352.93% | -153.47% | -588.64% | -6,309.62% | 0.00% | 0.00% | 0.00% | -750,101,900.00% | -10,900.00% | -3,200.00% | 0.00% |
| EPS | -12.66 | -76.96 | -75.06 | -154.45 | -115.88 | -162.09 | -279.17 | -223.73 | -721.04 | 0.00 | 0.00 | -56.07 | -32.56 | -109.48 | -108.07 | -100.77 | -203.93 | -384.10 | -284.78 | -433.58 | -543.70 | -662.23 | -3.26K | -1.18K | -2.09K | -6.57K | -3.06K | -703.37 |
| EPS Diluted | -12.66 | -76.89 | -75.06 | -154.45 | -115.88 | -162.09 | -279.17 | -320.56 | -721.04 | 0.00 | 0.00 | -56.07 | -32.56 | -109.48 | -108.07 | -100.77 | -203.93 | -384.10 | -284.78 | -433.58 | -543.70 | -662.23 | -3.26K | -1.18K | -2.09K | -6.57K | -3.06K | -703.37 |
| Weighted Avg Shares Out | 484.88K | 179.29K | 167.22K | 114.53K | 80.74K | 54.91K | 25.60K | 10.12K | 10.86K | 0.00 | 0.00 | 74.24K | 73.05K | 67.47K | 55.84K | 33.96K | 30.23K | 21.25K | 16.58K | 13.54K | 9.73K | 7.50K | 4.48K | 4.06K | 3.59K | 3.32K | 1.05K | 1.69K |
| Weighted Avg Shares Out (Dil) | 484.88K | 179.46K | 167.22K | 114.53K | 80.74K | 54.91K | 25.60K | 14.93K | 10.86K | 0.00 | 0.00 | 74.24K | 73.05K | 67.47K | 55.84K | 33.96K | 30.23K | 21.25K | 16.58K | 13.54K | 9.73K | 7.50K | 4.48K | 4.06K | 3.59K | 3.32K | 1.05K | 1.69K |
Soligenix Invited to Present at the Virtual Investor Summit Event
Focusing on 25 micro-cap companies with key catalysts and/or strong performance in the current market PRINCETON, N.J. , Jan. 19, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
7 Stocks to Add to Your 10x Watchlist
There are few things that get growth investors excited like the opportunity to invest in 10x stocks. By definition, these 10x stocks (also referred to as 10 baggers) can add huge gains to your portfolio.
Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference
Princeton, New Jersey--(Newsfile Corp. - November 11, 2022) - Investor Summit Group, today announced that Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company) will attend the Q4 Investor Summit live in NYC at the Sheraton Times Square. Jonathan Guarino, the...
Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma
Soligenix is an underfollowed biotech company trading at a $20 million market cap. The company is about to file an NDA for HyBryte, which I expect to become a first-in-class treatment in cutaneous T-cell lymphoma.
Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study
Soligenix Inc (NASDAQ: SNGX) announced the results of its Phase 3 FLASH study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL) had been published in the Journal of the American Medical Association (JAMA) Dermatology. "The peer-reviewed publication.
Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants
Soligenix Inc (NASDAQ: SNGX) announced the results of a booster vaccination study using CiVax (heat-stable COVID-19 subunit vaccine program) in non-human primates (NHPs). The data demonstrated rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including.
SG Blocks, Inc. Leads Round of Investment for Moliving, Inc.
JACKSONVILLE, Fla.--(BUSINESS WIRE)--SG Blocks, Inc. (NASDAQ: SGBX) (“SG Blocks” or the “Company”), a leading developer, designer, and fabricator of modular structures, and Moliving Inc., the world’s first luxury nomadic hospitality solution, today announced SG Blocks is leading Moliving’s seed round....
Soligenix to Present at the Q1 Virtual Investor Summit
PRINCETON, N.J., March 2, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its...
Soligenix, Inc. to Present at the Q1 Virtual Investor Summit
Princeton, New Jersey--(Newsfile Corp. - March 1, 2022) - Soligenix, Inc. (NASDAQ: SNGX) today announced that Jonathan Guarino, Senior Vice President & Chief Financial Officer will be attending the Q1 Virtual Investor Summit. During the presentation, Soligenix's Senior Vice President...
Soligenix to Present at the 2022 BIO CEO & Investor Conference
PRINCETON, N.J., Feb. 8, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President...
Source: https://incomestatements.info
Category: Stock Reports